21:26 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Stallergenes completes enrollment in Phase III trial of dust mite allergy tablet Actair

Stallergenes Greer plc (Euronext:STAGR) completed enrollment of over 1,600 patients in a Phase III trial of once-daily Actair house dust mites sublingual tablet (S-524101, STG320) to treat house dust mite-induced allergic rhinitis. The double-blind, placebo-controlled,...
05:17 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Actair regulatory update

Shionogi submitted a regulatory application in Japan for Actair house dust mite sublingual tablet to treat allergic rhinitis caused by house dust mites in patients ages 5-11. The sublingual immunotherapy tablets are already approved for...
20:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

STG320: Ph III data

Top-line data from a double-blind, Japanese Phase III trial in 438 patients ages 5-16 with perennial, house dust mite-induced allergic rhinitis showed that once-daily sublingual STG320 for 12 months met the primary endpoint of improving...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Circassia raises expectations

The largest-ever European biotech IPO - by Circassia Pharmaceuticals plc - plus three new filings have buysiders thinking the crack in a European IPO window could be widening. But if Circassia doesn't perform, it could...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

House dust mites sublingual immunotherapy tablet: Phase II/III data

Stallergenes said partner Shionogi reported data from the double-blind, Japanese Phase II/III S-524101 trial showing that house dust mites sublingual immunotherapy tablet met the primary endpoint of improving Average Adjusted Symptom Score over 1 year...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

House dust mites sublingual immunotherapy tablet: Phase II data

The dose-ranging, double-blind, Canadian Phase II VO67.10 trial in 355 adults with house dust mite allergic rhinitis showed that the once-daily 500 IR dose of Stallergenes' house dust mites sublingual immunotherapy tablet met the primary...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

3Q Financial Markets Preview: Flavored with Phase III

The upcoming clinical and regulatory calendar isn't as densely packed as it was in the first half. But biotech investors are looking especially to Phase III data across all market cap segments through year end. Among...
07:00 , Apr 4, 2011 |  BioCentury  |  Finance

ASCO and Beyond

The second quarter docket is full of clinical and regulatory milestones, as well as early reports of sales for a number of newly launched products. Foremost among the events this quarter is the American Society of...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

Stallergenes, Shionogi deal

Stallergenes granted Shionogi exclusive rights to develop and commercialize allergy candidate Actair in Japan and Taiwan. The sublingual desensitization tablet to treat house dust mites allergies is in Phase III testing. Shionogi also received...
00:42 , Sep 8, 2010 |  BC Extra  |  Company News

Stallergenes, Shionogi in allergy deal

Stallergenes S.A. (Euronext:GENP) granted Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507) exclusive rights in Japan and Taiwan to develop and commercialize house dust mite allergy candidate Actair. The sublingual desensitization tablet to treat house dust mites...